Description: IC50: 10 nM for human PPAR?BMS 687453 is a PPAR? agonist.

Description: IC50: 10 nM for human PPAR?BMS 687453 is a PPAR? agonist.

Description: IC50: 10 nM for human PPAR?BMS 687453 is a PPAR? agonist.

Description: Ki : 2 nM for RAR? Three retinoic acid receptors (RAR?, RAR? and RAR? and three retinoid X receptors, members of the nuclear receptor (NR) superfamily, mediate the biological effects of retinoic acids upon development, cell differentiation and proliferation, and homeostasis.

Description: Ki : 2 nM for RAR? Three retinoic acid receptors (RAR?, RAR? and RAR? and three retinoid X receptors, members of the nuclear receptor (NR) superfamily, mediate the biological effects of retinoic acids upon development, cell differentiation and proliferation, and homeostasis.

Description: Description:IC50: 1.7 nM/15 nM for Met/VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility.

Description: Description:IC50: 1.7 nM/15 nM for Met/VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility.

Description: Description:IC50: 1.7 nM/15 nM for Met/VEGFR2 The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor is important for cell growth, survival, and motility.

Description: IC50: 13 nMBMS-582949 is a p38 MAPK inhibitorp38R MAP kinase plays a key role in regulating the biosynthesis of various inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1?.

Description: IC50: 13 nMBMS-582949 is a p38 MAPK inhibitorp38R MAP kinase plays a key role in regulating the biosynthesis of various inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1?.

Description: IC50: 13 nMBMS-582949 is a p38 MAPK inhibitorp38R MAP kinase plays a key role in regulating the biosynthesis of various inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-1?.

Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.

Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.

Description: BMS-303141 is a potent inhibitor of ATP-citrate lyase with IC50 value of 0.13 ?M [1]. ATP-citrate lyase (ACL) is a cytosolic enzyme that responsible for the production of cytosolic acetyl-CoA, a precursor required for de novo biosyntheses of cholesterol and fatty acids.

Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.

Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.

Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.

Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.

Description: BMS-794833 is a potent ATP competitive, dual inhibitor of c-Met and VEGFR2 (IC50 = 1.7 nM and 15 nM, respectively). It also has inhibitory effect on Ron, Axl and Flt3 (IC50 50% TGI for at least one tumor doubling time without significant toxicity in 14 days.

Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.

Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.

Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.

Description: BMS-378806 is a novel attachment inhibitor of HIV with EC50 values of 2.68±1.64nM, 26.5±3.5nM.

Description: BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI.

Description: BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI.

Description: BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI.

Description: BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI.

Description: BMS 777607 is a novel, selective and orally available ATP-competitive MET kinase inhibitor that primarily targets several MET family members, including RON, MET, Tyro-3 and AxI.

Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki <2 nmol/L[1]. The efficacy of BMS-754807 on normal tissues and tumor cell cycle is believed to be different from the effects of continuous inhibition by anti-IGF-1R antibodies.

Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki <2 nmol/L[1]. The efficacy of BMS-754807 on normal tissues and tumor cell cycle is believed to be different from the effects of continuous inhibition by anti-IGF-1R antibodies.

Description: BMS-754807 is a potent and small molecular inhibitor which targets the IGF-1R/IR family kinases with Ki <2 nmol/L[1]. The efficacy of BMS-754807 on normal tissues and tumor cell cycle is believed to be different from the effects of continuous inhibition by anti-IGF-1R antibodies.

Description: BMS-536924 is a novel inhibitor of IGF-1R with IC50 value of 100nM [1].It has been found that BMS-536924 has cell toxicity in OVCAR-3 and OVCAR-4 cell lines.

Description: BMS-536924 is a novel inhibitor of IGF-1R with IC50 value of 100nM [1].It has been found that BMS-536924 has cell toxicity in OVCAR-3 and OVCAR-4 cell lines.

Description: BMS-536924 is a novel inhibitor of IGF-1R with IC50 value of 100nM [1].It has been found that BMS-536924 has cell toxicity in OVCAR-3 and OVCAR-4 cell lines.

Description: BMS-536924 is a novel inhibitor of IGF-1R with IC50 value of 100nM [1].It has been found that BMS-536924 has cell toxicity in OVCAR-3 and OVCAR-4 cell lines.

Description: BMS-509744 is a selective inhibitor of ITK with IC50 value of 15 nM [1].ITK (IL-2-inducible T cell kinase) is an enzyme and plays an important role in T cell receptor signaling.

Description: BMS-509744 is a selective inhibitor of ITK with IC50 value of 15 nM [1].ITK (IL-2-inducible T cell kinase) is an enzyme and plays an important role in T cell receptor signaling.

Description: BMS-509744 is a selective inhibitor of ITK with IC50 value of 15 nM [1].ITK (IL-2-inducible T cell kinase) is an enzyme and plays an important role in T cell receptor signaling.

Description: EC50HIV-1 attachment inhibitors represent a new class of entry inhibitors that prevent the initial interaction between virus and host cell by binding to the viral envelope protein gp120 and blocking attachment of the virus to the CD4 receptor on CD4+ T-cells.

Description: EC50HIV-1 attachment inhibitors represent a new class of entry inhibitors that prevent the initial interaction between virus and host cell by binding to the viral envelope protein gp120 and blocking attachment of the virus to the CD4 receptor on CD4+ T-cells.

Description: EC50HIV-1 attachment inhibitors represent a new class of entry inhibitors that prevent the initial interaction between virus and host cell by binding to the viral envelope protein gp120 and blocking attachment of the virus to the CD4 receptor on CD4+ T-cells.

Description: EC50HIV-1 attachment inhibitors represent a new class of entry inhibitors that prevent the initial interaction between virus and host cell by binding to the viral envelope protein gp120 and blocking attachment of the virus to the CD4 receptor on CD4+ T-cells.

Description: BMS-663068 is a small-molecule attachment inhibitor of HIV-1 gp120 with IC50 value of [1].The first step of HIV-1 virus to entry host cells is the binding of the viral gp120 envelope glycopeptide to the CD4 receptor of host cell.

Description: BMS-663068 is a small-molecule attachment inhibitor of HIV-1 gp120 with IC50 value of [1].The first step of HIV-1 virus to entry host cells is the binding of the viral gp120 envelope glycopeptide to the CD4 receptor of host cell.

Description: BMS-690514, a potent inhibitor of human epidermal growth factor receptor (HER/EGFR).

Description: BMS-690514, a potent inhibitor of human epidermal growth factor receptor (HER/EGFR).

Description: BMS-690514, a potent inhibitor of human epidermal growth factor receptor (HER/EGFR).

Description: BMS-690514, a potent inhibitor of human epidermal growth factor receptor (HER/EGFR).

Description: BMS-833923 is an orally bioavailable and selective antagonist of smoothened (SMO) with IC50 value of 5.8 nM in NIH3T3 cell line [1].The Hedgehog (Hh) signaling is a critical pathway involved in embryonic development and in tissue maintenance and repair in adults.

Description: BMS-833923 is an orally bioavailable and selective antagonist of smoothened (SMO) with IC50 value of 5.8 nM in NIH3T3 cell line [1].The Hedgehog (Hh) signaling is a critical pathway involved in embryonic development and in tissue maintenance and repair in adults.

Description: BMS-833923 is an orally bioavailable and selective antagonist of smoothened (SMO) with IC50 value of 5.8 nM in NIH3T3 cell line [1].The Hedgehog (Hh) signaling is a critical pathway involved in embryonic development and in tissue maintenance and repair in adults.

Description: BMS-833923 is an orally bioavailable and selective antagonist of smoothened (SMO) with IC50 value of 5.8 nM in NIH3T3 cell line [1].The Hedgehog (Hh) signaling is a critical pathway involved in embryonic development and in tissue maintenance and repair in adults.

Description: BMS-927711 is an orally potent CGRP receptor antagonist with IC50 of 0.14 nM. [1]Calcitonin gene-related peptide CGRP is a 37 amino acid peptide widely distributed in the nervous system, which is a highly potent vasodilator that has been directly implicated in the pathology of migraine.

Description: BMS-927711 is an orally potent CGRP receptor antagonist with IC50 of 0.14 nM. [1]Calcitonin gene-related peptide CGRP is a 37 amino acid peptide widely distributed in the nervous system, which is a highly potent vasodilator that has been directly implicated in the pathology of migraine.